ES2064470T3 - Liposomas en los cuales se inhibe la adsorcion de proteinas. - Google Patents

Liposomas en los cuales se inhibe la adsorcion de proteinas.

Info

Publication number
ES2064470T3
ES2064470T3 ES89402290T ES89402290T ES2064470T3 ES 2064470 T3 ES2064470 T3 ES 2064470T3 ES 89402290 T ES89402290 T ES 89402290T ES 89402290 T ES89402290 T ES 89402290T ES 2064470 T3 ES2064470 T3 ES 2064470T3
Authority
ES
Spain
Prior art keywords
liposomes
liposoma
adsorption
proteins
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89402290T
Other languages
English (en)
Inventor
Hiroshi Yoshida
Hiroshi Goto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Application granted granted Critical
Publication of ES2064470T3 publication Critical patent/ES2064470T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

SE DESCRIBEN AGENTES PARA INHIBIR LA ADSORCION DE PROTEINAS EN LA SIPERFICIE DE LIPOSOMAS Y LIPOSOMAS QUE ESTAN LIBRES DE AGLUTINACION, POR UNION DE DICHO AGENTE DE INHIBICION A LA SUPERFICIE. LOS AGENTES DE INHIBICION ANTES MENCIONADOS CONTIENEN UNA PARTE HIDROFOBA Y UNA PARTE DE CADENA MACROMOLECULAR HIDROFILA. LA ADSORCION DE PROTEINAS DE PLASMA SOBRE LOS LIPOSOMAS SE INHIBE DEBIDO A LA PARTE HIDROFILA EXPUESTA EN LA SUPERFICIE DEL LIPOSOMA, CON EL RESULTADO DE QUE SE IMPIDE LA AGLUTINACION DE LOS LIPOSOMAS EN EL PLASMA. POR TANTO, NO HAY PELIGRO DE EMBOLISMO EN LOS VASOS SANGUINEOS QUE INHIBEN EL FLUJO SANGUINEO CUANDO LOS LIPOSOMAS SE INTRODUCEN EN EL CUERPO VIVO. CONSIGUIENTEMENTE, LOS LIPOSOMAS SON ESPECIALMENTE MUY UTILES COMO ERITROCITOS ARTIFICIALES, POR LO QUE ES NECESARIO UNA GRAN DOSIS DE LIPOSOMAS PARA ADMINISTRACION. ADEMAS, CUANDO LOS LIPOSOMAS SE INTRODUCEN EN EL CUERPO VIVO, LA PROTEINA ANTICUERPO (INMUNOGLOBULINA) AL LIPOSOMA, QUE ES UN ANTIGENO, ES ADSORBIDA EN EL LIPOSOMA PARA PRODUCIR EL RECONOCIMIENTO DE CUERPOS EXTRAÑOS EN LOS FAGOCITOS (MACROFAGO), CON EL RESULTADO DE QUE LOS LIPOSOMAS SE INCLUYEN EN EL MACROFAGO Y DESAPARECEN EN UN CORTO PERIODO DE TIEMPO. ASI, LA INHIBICION DE LA ADSORCION DE PROTEINA EN LIPOSOMA PUEDE RETRASAR LA DESAPARICION DEL LIPOSOMA EN EL PLASMA. ADEMAS, SE DESCRIBE UN METODO PARA PREPARAR LOS LIPOSOMAS ANTES DESCRITOS.
ES89402290T 1988-08-11 1989-08-11 Liposomas en los cuales se inhibe la adsorcion de proteinas. Expired - Lifetime ES2064470T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19891588 1988-08-11
JP1063507A JPH0720857B2 (ja) 1988-08-11 1989-03-17 リポソームおよびその製法

Publications (1)

Publication Number Publication Date
ES2064470T3 true ES2064470T3 (es) 1995-02-01

Family

ID=26404636

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89402290T Expired - Lifetime ES2064470T3 (es) 1988-08-11 1989-08-11 Liposomas en los cuales se inhibe la adsorcion de proteinas.

Country Status (5)

Country Link
US (3) US5676971A (es)
EP (1) EP0354855B1 (es)
JP (1) JPH0720857B2 (es)
DE (1) DE68919772T2 (es)
ES (1) ES2064470T3 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20010051183A1 (en) * 1989-10-20 2001-12-13 Alza Corporation Liposomes with enhanced circulation time and method of treatment
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5380536A (en) * 1990-10-15 1995-01-10 The Board Of Regents, The University Of Texas System Biocompatible microcapsules
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5626863A (en) * 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
DE69329594T2 (de) 1992-02-28 2001-05-31 Board Of Regents, The University Of Texas System Photopolymerinierbare, biologisch abbaubare hydrogele als gewebekontaktmaterialien und trägerstoffe für kontrollierte freisetzung
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
GB9509016D0 (en) * 1995-05-03 1995-06-21 Royal Free Hosp School Med Tissue entrapment
US6673364B1 (en) 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
DE69628731T3 (de) * 1995-11-01 2012-09-20 Bracco Suisse S.A. Gezielte magnetisch markierte molekularmarkersysteme als nmr-bilderzeugungsmittel
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンｂ運搬体
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US6224903B1 (en) 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6103599A (en) * 1997-07-25 2000-08-15 Silicon Genesis Corporation Planarizing technique for multilayered substrates
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
WO1999033493A1 (en) * 1997-12-23 1999-07-08 Inex Pharmaceuticals Corporation Polyamide oligomers
CA2309373A1 (en) * 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
WO2001041738A2 (en) * 1999-12-10 2001-06-14 Celator Technologies Inc. Lipid carrier compositions with protected surface reactive functions
WO2002038128A1 (fr) * 2000-11-10 2002-05-16 Japan Science And Technology Corporation Procede de preparation d'une dispersion de microsome
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
JPWO2003015753A1 (ja) * 2001-08-20 2004-12-02 テルモ株式会社 リポソーム製剤
EP1483277A4 (en) 2002-02-15 2007-10-03 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF
US20040005641A1 (en) * 2002-02-15 2004-01-08 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2003211113B2 (en) * 2002-02-15 2007-08-09 Merckle Gmbh Antibiotic conjugates
US20040186063A1 (en) * 2002-02-15 2004-09-23 Hans-Jurgen Gutke Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2003233396B2 (en) * 2002-03-13 2007-05-24 Thomas Skold Water-based delivery systems
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
DE60335469D1 (de) 2002-07-02 2011-02-03 Univ Texas Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
US20060141019A1 (en) * 2002-11-15 2006-06-29 Toshiya Kai Liposome
SG159387A1 (en) 2002-11-26 2010-03-30 Biocon Ltd In Modified natriuretic compounds, conjugates, and uses thereof
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
DE60330745D1 (de) 2002-12-31 2010-02-11 Bharat Serums & Vaccines Ltd Nicht-pegylierte lang-zirkulierende Liposome
JP2004307404A (ja) 2003-04-08 2004-11-04 Nipro Corp 人工酸素運搬体を含む医薬組成物
US7696359B2 (en) * 2003-09-03 2010-04-13 Kyowa Hakko Kirin Co., Ltd. Compound modified with glycerol derivative
WO2005092388A1 (ja) * 2004-03-26 2005-10-06 Terumo Kabushiki Kaisha リポソーム製剤
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US7749485B2 (en) 2004-06-03 2010-07-06 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
JP4692983B2 (ja) 2004-07-12 2011-06-01 独立行政法人科学技術振興機構 リポソーム封入物質がエンドソームから脱出可能なリポソーム
AU2005304914B2 (en) 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
EP1813288B1 (en) * 2004-11-18 2018-07-18 Terumo Kabushiki Kaisha Medicinal composition, medicinal preparation, and combination preparation
EP1842585A4 (en) * 2005-01-28 2013-05-29 Kyowa Hakko Kirin Co Ltd METHOD FOR PRODUCING A SURFACE OF FINE PARTICLES MODIFIED WITH A WATER SOLUBLE SUBSTANCE
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20090305409A1 (en) 2005-03-24 2009-12-10 National University Corporation Hokkaido University Liposome Capable of Effective Delivery of Given Substance Into Nucleus
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
RU2008106915A (ru) * 2005-07-26 2009-09-10 Меркле Гмбх (De) Макролидные конъюгаты пирролиновых и индолизиновых соединений
US8591457B2 (en) 2005-08-10 2013-11-26 Alza Corporation Method for making a needle-free jet injection drug delivery device
US20070154403A1 (en) * 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
JP5072275B2 (ja) * 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
EP2127640A1 (en) * 2008-05-27 2009-12-02 Koninklijke Philips Electronics N.V. Azide modified proteins
JP5094696B2 (ja) * 2008-12-18 2012-12-12 テルモ株式会社 ヘモグロビン含有リポソーム懸濁液中のヘモグロビン及びヘモグロビン類縁物質の分離定量方法。
WO2010110471A1 (ja) * 2009-03-23 2010-09-30 国立大学法人北海道大学 脂質膜構造体
EP2522366B1 (en) 2010-01-08 2018-10-31 FUJIFILM Corporation Targeting agent for tumor site
US8981044B2 (en) 2010-04-21 2015-03-17 National University Corporation Hokkaido University Lipid membrane structure having intranuclear migrating property
WO2012078695A2 (en) 2010-12-06 2012-06-14 Merrimack Pharmaceuticals, Inc. Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
JP6057317B2 (ja) * 2012-04-05 2017-01-11 セイコーエプソン株式会社 分離装置
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
WO2014015027A1 (en) 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
MX2015006931A (es) 2012-12-03 2016-07-05 Merrimack Pharmaceuticals Inc Terapia combinada para tratar cánceres her2-positivos.
CN107405305B (zh) 2015-01-20 2020-12-25 泰特拉德姆集团有限责任公司 提供粘膜和皮肤屏障恢复的通用局部药物递送载体和多因子组织保湿剂
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
ES3036518T3 (en) 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
TWI754659B (zh) 2016-08-08 2022-02-11 台灣微脂體股份有限公司 用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
KR102676927B1 (ko) 2017-06-15 2024-06-24 국립대학법인 홋가이도 다이가쿠 siRNA 세포 내 송달을 위한 지질막 구조체

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1578776A (en) * 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4598051A (en) * 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
DE43327T1 (de) * 1980-07-01 1983-01-05 L'Oreal, 75008 Paris Verfahren zur herstellung stabiler dispersionen in einer waessrigen phase von mindestens einer fluessigen, nicht mit wasser mischbaren phase und die entsprechenden dispersionen.
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
JPS59137409A (ja) * 1983-01-27 1984-08-07 Green Cross Corp:The ベンゾジアゼピン系化合物脂肪小体製剤
JPS6058915A (ja) * 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
JPS6072830A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
US4971803A (en) * 1985-04-08 1990-11-20 California Institute Of Technology Lamellar vesicles formed of cholesterol derivatives
AT393169B (de) * 1985-06-05 1991-08-26 Staudinger Gernot Verfahren und vorrichtung zur korngroessenanalyse
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
JPS6295134A (ja) * 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
AU6593386A (en) * 1985-10-24 1987-05-19 Research Corp. Ltd. Biochemical reagent
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4776991A (en) * 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4855090A (en) * 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
US4948590A (en) * 1987-06-09 1990-08-14 Yale University Avidin or streptavidin conjugated liposomes
US4921838A (en) * 1987-06-16 1990-05-01 Trustees Of Boston University Angiogenic and blood perfusion inducing properties of amphiphilic compounds
US4853228A (en) * 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
US4915951A (en) * 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US4931361A (en) * 1988-11-18 1990-06-05 California Institute Of Technology Cryoprotective reagents in freeze-drying membranes
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0525188B1 (en) * 1990-04-18 1995-03-01 Takeda Chemical Industries, Ltd. Liposome composition
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム

Also Published As

Publication number Publication date
DE68919772T2 (de) 1995-07-13
EP0354855B1 (en) 1994-12-07
JPH0720857B2 (ja) 1995-03-08
US5676971A (en) 1997-10-14
EP0354855A2 (en) 1990-02-14
US5593622A (en) 1997-01-14
US5846458A (en) 1998-12-08
JPH02149512A (ja) 1990-06-08
EP0354855A3 (en) 1991-06-05
DE68919772D1 (de) 1995-01-19

Similar Documents

Publication Publication Date Title
EP0354855A3 (en) Liposomes on which adsorption of proteins is inhibited
Horowits et al. A physiological role for titin and nebulin in skeletal muscle
ATE72629T1 (de) Cyclosporin enthaltende pharmazeutische zubereitung.
Hope et al. Human β-thromboglobulin inhibits PGI2 production and binds to a specific site in bovine aortic endothelial cells
AU1627588A (en) Biodadhesion drug carriers for endothelial and epithelial uptake and lesional localization of therapeutic and diagnostic agents
DE3872334D1 (de) Stabilisierte humanprotein-praeparate.
ATE70718T1 (de) Pharmakadepotpraeparat.
DE69410630D1 (de) Vorrichtung zur frühembryonalen in ovo injektion
ES2105225T3 (es) Control de los residuos de medicamentos veterinarios en la carne fresca.
DK0522091T3 (da) Anvendelse af et MBP-peptid til fremstilling af et medikament til behandling af multipel sklerose
Konturek Gastrin-like pentapeptide ICI 50 123: a potent gastric stimulant in man
Fisher et al. Passive cutaneous anaphylaxis (PCA) in the guinea pig: An immunologic and pathologic study
Barrett et al. Restoration of complement function in vivo by plasma infusion in factor I (C3b inactivator) deficiency
Southam et al. Effect of nitrogen mustard on serum complement in vitro and in patients with neoplastic disease
ES2169783T3 (es) Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2.
Lenninger Effects of parasympathomimetic agents and vagal stimulation on the flow in the pancreatic duct of the cat
EP0308926A3 (en) Method of determining behavior of drugs in living bodies
Rosell et al. The rate of disappearance of vasoconstrictor responses to sympathetic chain stimulation after reserpine treatment
Oken et al. Biologically effective immunization against angiotensin
Wurzel et al. Vasoactive properties of plasma protein fractions
ES2060927T3 (es) Anticuerpos contra la fibrina; peptidos inmunogenos adecuados para preparar los anticuerpos, metodo para determinar fibrina y preparacion farmaceutica basada en los anticuerpos.
ES2058931T3 (es) Un reactivo para la deteccion de actividad fibrinolitica.
Valenzuela et al. Effect of big and little gastrins on pancreatic and gastric secretion
Reid et al. THE INFLUENCE OF IMMUNOSUPPRESSION AND ALLO-GRAFTING ON VIRUS-INDUCED LYMPHATIC LEUKEMIA IN MICE
RU2064784C1 (ru) Протез сосуда

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 354855

Country of ref document: ES